{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:35:19Z","timestamp":1782894919225,"version":"3.54.5"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic cell transplantation (alloHCT) recipients are at increased\u00a0risk of severe COVID-19. Although vaccination is strongly recommended, immune responses may vary and can be affected by clinical and treatment-related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this longitudinal, single-center study, we analyzed IgG, IgM, and IgA antibody kinetics to severe acute respiratory syndrome-Corona virus-2 (SARS-CoV-2) spike-1, receptor binding domain (RBD), and nucleocapsid proteins in 354 alloHCT patients and 647 healthy controls by ELISA. A total of 1,364 serum samples were collected before and after one, two, and three doses of mRNA, adenovirus vector, and\/or protein-based vaccines. Clinical parameters, including age, conditioning regimen, immunosuppressive therapy, graft-versus-host disease (GVHD), donor type, time since transplantation, diagnosis, and laboratory parameters were evaluated for their influence on antibody responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anti-spike-1 IgG responses increased progressively: 27% of patients versus 28% of controls seroconverted after the first vaccination, 65% versus 59% after the second, and 93% versus 98% after the third. After three doses, no significant differences in IgG prevalence or reactivity remained between groups. IgM and IgA responses were infrequent. Multivariate analysis identified diagnosis, shorter interval between transplantation or vaccination and antibody testing, and lower lymphocyte count as negative predictors after the first vaccination. No negative predictors were detected after the third dose. Antibody levels remained stable for at least six months following the third vaccination. Breakthrough infections occurred but were mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AlloHCT recipients achieve humoral immunity comparable to healthy individuals after three vaccine doses, supporting efficacy and safety of repeated SARS-CoV-2 vaccination in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1829281","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:44:26Z","timestamp":1782888266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Humoral responses to SARS-CoV-2 vaccination in allogeneic hematopoietic cell transplantation patients resemble that of healthy individuals"],"prefix":"10.3389","volume":"17","author":[{"given":"Claus-Philipp","family":"Maier","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]},{"name":"Department of Hematology, Oncology, Gastroenterology, Nephrology, Rheumatology, Children\u2019s Hospital, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Preuss","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Reuss","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Welter","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Pecher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, Medical Clinic, University of Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101399","article-title":"COVID-19 and HSCT (Hematopoietic stem cell transplant)","volume":"35","author":"Strasfeld","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jtct.2022.01.019","article-title":"Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation","volume":"28","author":"Huang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16020022","article-title":"Monitoring humoral response following BNT162b2 mRNA vaccination against SARS-CoV-2 in hematopoietic stem-cell transplantation patients: a single-center prospective study along with a brief review of current literature","volume":"16","author":"Asimakopoulos","year":"2024","journal-title":"Hematol Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtct.2022.06.012","article-title":"Predictors of Covid-19 vaccination response after In-Vivo T-cell-depleted stem cell transplantation","volume":"28","author":"Chaekal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1174289","article-title":"Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation","volume":"14","author":"Hutter-Kronke","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03648-1","article-title":"Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts","volume":"118","author":"Takagi","year":"2023","journal-title":"Int J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-022-01300-9","article-title":"Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1100468","article-title":"Allogeneic hematopoietic stem cell transplantation in the COVID-19 era","volume":"14","author":"Bordat","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13431","article-title":"Structural immunology of SARS-CoV-2","volume":"329","author":"Yuan","year":"2025","journal-title":"Immunol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jtct.2021.07.008","article-title":"Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients","volume":"27","author":"Ali","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101534","article-title":"Successful SARS-CoV-2 mRNA vaccination program in allogeneic hematopoietic stem cell transplant recipients-a retrospective single-center analysis","volume":"11","author":"Nikoloudis","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3006","article-title":"Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients","volume":"40","author":"Chevallier","year":"2022","journal-title":"Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-022-01250-2","article-title":"Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients","volume":"15","author":"Leclerc","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.005","article-title":"Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients","volume":"40","author":"Canti","year":"2022","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280494","article-title":"Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation","volume":"107","author":"Einarsdottir","year":"2022","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-21-0142","article-title":"Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.06.020","article-title":"Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis","volume":"74","author":"Klein","year":"2013","journal-title":"Hum Immunol"},{"key":"B21","volume-title":"Wahrscheinlichkeitsrechnung Und Inferenzstatistik","author":"Nachtigall","year":"2004"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03325-9","article-title":"Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation","volume":"115","author":"Tsushima","year":"2022","journal-title":"Int J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070726","article-title":"COVID-19 vaccine response in Allo-HSCT recipients: insights from a real-world prospective cohort study","volume":"13","author":"Savas","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010349","article-title":"Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis","volume":"7","author":"Meejun","year":"2023","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17911","article-title":"Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant","volume":"196","author":"Le Bourgeois","year":"2022","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00274-x","article-title":"Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT","volume":"8","author":"Redjoul","year":"2021","journal-title":"Lancet Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3324\/haematol.2022.280619","article-title":"Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and \"booster\" dose","volume":"107","author":"Attolico","year":"2022","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0288557","article-title":"Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study","volume":"18","author":"Amellal","year":"2023","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01432-4","article-title":"A correlate of protection for SARS-CoV-2 vaccines is urgently needed","volume":"27","author":"Krammer","year":"2021","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842912","article-title":"Decline of humoral and cellular immune responses against SARS-CoV-2\u20136 months after full BNT162b2 vaccination in hospital healthcare workers","volume":"13","author":"Bonnet","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00035.2015","article-title":"Sex and gender impact immune responses to vaccines among the elderly","volume":"30","author":"Fink","year":"2015","journal-title":"Physiol (Bethesda)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111782","article-title":"Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation","volume":"10","author":"Meyer","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014232","article-title":"Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients","volume":"139","author":"Maillard","year":"2022","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00605-1","article-title":"Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning","volume":"12","author":"Morsink","year":"2022","journal-title":"Blood Cancer J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01466-9","article-title":"Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"56","author":"Mamez","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.255","article-title":"Background to hematopoietic cell transplantation, including post transplant immune recovery","volume":"44","author":"Mackall","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020325","article-title":"Two doses of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral response and serological conversion predictors","volume":"14","author":"Majcherek","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01946-0","article-title":"SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination","volume":"58","author":"Pinana","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26769","article-title":"Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: a Japanese multicenter observational study","volume":"98","author":"Mori","year":"2023","journal-title":"Am J Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem-Tov","year":"2022","journal-title":"Br J Haematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmi.2021.10.007","article-title":"Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation","volume":"28","author":"Yeshurun","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013445","article-title":"Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients","volume":"139","author":"Liebers","year":"2022","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-Cov-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101075","article-title":"Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients","volume":"9","author":"Lindemann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ccell.2021.10.002","article-title":"Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients","volume":"39","author":"Harrington","year":"2021","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006937","article-title":"Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity","volume":"6","author":"Einarsdottir","year":"2022","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:44:27Z","timestamp":1782888267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2026.1829281"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1829281","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1829281"}}